From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases
暂无分享,去创建一个
I. Pavord | S. Yancey | E. Bel | O. Keene | M. Wechsler | A. Papi | M. Liu | A. Bourdin | F. Roufosse | Joseph K. Han | N. Martin | J. Steinfeld | R. Chan
[1] M. Humbert,et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) , 2021, European Respiratory Journal.
[2] I. Pavord,et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO , 2021, International journal of chronic obstructive pulmonary disease.
[3] S. Yancey,et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Respiratory medicine.
[4] J. Butterfield,et al. Impact of mepolizumab on symptom severity in patients with hypereosinophilic syndrome , 2021 .
[5] D. Price,et al. Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study , 2021, Respiratory Research.
[6] T. Kawakami,et al. Early add‐on administration of mepolizumab and intravenous immunoglobulin effective in treating eosinophilic granulomatosis with polyangiitis , 2020, The Journal of dermatology.
[7] L. Koenderman,et al. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait , 2020, Thorax.
[8] O. Matsuno,et al. Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps. , 2020, Pulmonary pharmacology & therapeutics.
[9] I. Pavord,et al. Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On The Path to Personalized Medicine. , 2020, The journal of allergy and clinical immunology. In practice.
[10] P. Howarth,et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis , 2020, European Respiratory Journal.
[11] N. Lombardo,et al. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma , 2020, International journal of immunopathology and pharmacology.
[12] A. Amini,et al. Mepolizumab as Possible Treatment for Allergic Bronchopulmonary Aspergillosis: A Review of Eight Cases , 2020, Cureus.
[13] K. Tan,et al. The role of preoperative blood eosinophil counts in distinguishing chronic rhinosinusitis with nasal polyps phenotypes , 2020, International forum of allergy & rhinology.
[14] H. J. Kim,et al. The Emerging Role of Eosinophils as Multifunctional Leukocytes in Health and Disease , 2020, Immune network.
[15] P. Malfertheiner,et al. A Network Meta-Analysis of Randomized Controlled Trials on the Treatment of Eosinophilic Esophagitis in Adults and Children , 2020, Journal of clinical gastroenterology.
[16] F. Albers,et al. Factors that affect blood eosinophil counts in a non-asthmatic population: Post hoc analysis of data from Brazil , 2020, The World Allergy Organization journal.
[17] S. Yancey,et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial , 2020, The Journal of allergy and clinical immunology.
[18] J. Kavanagh,et al. Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[19] M. Mantero,et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. , 2020, Respiratory medicine.
[20] J. Getsy,et al. Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis , 2020, Allergy.
[21] I. Pavord,et al. Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.
[22] C. Bachert,et al. Biologics for chronic rhinosinusitis with nasal polyps. , 2020, The Journal of allergy and clinical immunology.
[23] N. Tutar,et al. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study , 2020, Turkish journal of medical sciences.
[24] F. Albers,et al. Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sino-nasal and asthma outcomes with mepolizumab therapy. , 2020, The Journal of allergy and clinical immunology.
[25] C. Pilette,et al. Real-Life Study of Mepolizumab in Idiopathic Chronic Eosinophilic Pneumonia , 2020, Lung.
[26] D. Wang,et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. , 2020, Rhinology.
[27] M. Humbert,et al. Efficacy of intravenous reslizumab in oral corticosteroid-dependent asthma. , 2020, The journal of allergy and clinical immunology. In practice.
[28] G. Criner,et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. , 2020, The Lancet. Respiratory medicine.
[29] G. Braunstahl,et al. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.
[30] H. Ortega,et al. Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs , 2020, Journal of asthma and allergy.
[31] K. Zhuo,et al. Prevalence and Baseline Clinical Characteristics of Eosinophilic Chronic Obstructive Pulmonary Disease: A Meta-Analysis and Systematic Review , 2019, Front. Med..
[32] William J. Astle,et al. Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status , 2019, Nature Communications.
[33] Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level (MATINEE) , 2019, Case Medical Research.
[34] T. Iwamoto,et al. Update on eosinophilic granulomatosis with polyangiitis. , 2019, Allergology international : official journal of the Japanese Society of Allergology.
[35] J. Gotlib,et al. World Health Organization‐defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management , 2019, American journal of hematology.
[36] Abdulrahman M. Nasiri,et al. Mepolizumab as an effective treatment for Kimura's disease associated with ulcerative colitis: A case report , 2019, Journal of family medicine and primary care.
[37] Y. Tokura,et al. Successful control of severe eosinophilic granulomatosis with polyangiitis in a pregnancy and perinatal period: A use of mepolizumab , 2019, The Journal of dermatology.
[38] F. Albers,et al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study. , 2019, Clinical therapeutics.
[39] A. Vaglio,et al. New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group , 2019, Internal and Emergency Medicine.
[40] M. Gokhale,et al. Prevalence of Eosinophilic Granulomatosis With Polyangiitis and Associated Health Care Utilization Among Patients With Concomitant Asthma in US Commercial Claims Database , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[41] S. Yancey,et al. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. , 2019, The Journal of allergy and clinical immunology.
[42] Joseph K. Han,et al. Analysis of Histopathological Endotyping for Chronic Rhinosinusitis Phenotypes Based on Comorbid Asthma and Allergic Rhinitis , 2019, American journal of rhinology & allergy.
[43] M. Fay,et al. Benralizumab for PDGFRA‐Negative Hypereosinophilic Syndrome , 2019, The New England journal of medicine.
[44] S. Szefler,et al. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[45] Meilan K. Han,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 , 2019, European Respiratory Journal.
[46] G. E. Carpagnano,et al. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab , 2019, Journal of asthma and allergy.
[47] E. Bateman,et al. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. , 2019, The journal of allergy and clinical immunology. In practice.
[48] M. Kohanski,et al. Biomarkers in Chronic Rhinosinusitis with Nasal Polyps. , 2018, Immunology and allergy clinics of North America.
[49] K. Rabe,et al. Inhaled corticosteroids in COPD: friend or foe? , 2018, European Respiratory Journal.
[50] M. Fay,et al. Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome. , 2018, The journal of allergy and clinical immunology. In practice.
[51] Alex K. Shalek,et al. Allergic inflammatory memory in human respiratory epithelial progenitor cells , 2018, Nature.
[52] James J. Lee,et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease , 2018, Journal of leukocyte biology.
[53] F. Roufosse. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma , 2018, Front. Med..
[54] I. Pavord,et al. Associations between blood eosinophils and decline in lung function among adults with and without asthma , 2018, European Respiratory Journal.
[55] T. Zuberbier,et al. Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[56] E. Hoffman,et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction , 2018, The Journal of clinical investigation.
[57] Oliver N Keene,et al. Biomarkers for severe eosinophilic asthma , 2017, The Journal of allergy and clinical immunology.
[58] A. White,et al. Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.
[59] J. Gotlib. World Health Organization‐defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management , 2017, American journal of hematology.
[60] I. Pavord,et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease , 2017, The New England journal of medicine.
[61] I. Hirsch,et al. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies , 2017, Current medical research and opinion.
[62] K. Rabe,et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.
[63] S. Yancey,et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.
[64] F. Albers,et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.
[65] L. Rudmik,et al. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis , 2017, The Laryngoscope.
[66] R. Schleimer. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. , 2017, Annual review of pathology.
[67] William J. Astle,et al. Allelic Landscape of Human Blood Cell Trait Variation and Links , 2016 .
[68] J. Corren,et al. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts. , 2016, Chest.
[69] C. Lemière,et al. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. , 2016, Chest.
[70] H. Ortega,et al. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.
[71] Christopher E Brightling,et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. , 2016, The Lancet. Respiratory medicine.
[72] E. Bel,et al. Clinical profile of patients with adult-onset eosinophilic asthma , 2016, ERJ Open Research.
[73] Q. Lu,et al. A Player and Coordinator: The Versatile Roles of Eosinophils in the Immune System , 2016, Transfusion Medicine and Hemotherapy.
[74] C. Galeone,et al. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases , 2015, Journal of asthma and allergy.
[75] I. Pavord,et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. , 2015, The Lancet. Respiratory medicine.
[76] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[77] R. Lutter,et al. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma , 2014, Thorax.
[78] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[79] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[80] I. Pavord,et al. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis , 2014, European Respiratory Journal.
[81] K. Acharya,et al. Eosinophil Granule Proteins: Form and Function , 2014, The Journal of Biological Chemistry.
[82] S. Aceves. Remodeling and Fibrosis in Chronic Eosinophil Inflammation , 2014, Digestive Diseases.
[83] M. Citardi,et al. Analysis of comorbidities and objective parameters in refractory chronic rhinosinusitis , 2013, The Laryngoscope.
[84] J. Bird,et al. Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.
[85] J. Sheikh,et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. , 2013, The Journal of allergy and clinical immunology.
[86] Joseph K. Han,et al. Subclassification of chronic rhinosinusitis , 2013, The Laryngoscope.
[87] M. Rothenberg,et al. Targeting eosinophils in allergy, inflammation and beyond , 2013, Nature Reviews Drug Discovery.
[88] T. Haferlach,et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, Journal of Allergy and Clinical Immunology.
[89] Christopher E Brightling,et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.
[90] P. Weller,et al. Eosinophils and disease pathogenesis. , 2012, Seminars in hematology.
[91] Zheng Liu,et al. Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults , 2012, The Laryngoscope.
[92] Christopher E Brightling,et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.
[93] F. Moosig,et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. , 2011, Annals of internal medicine.
[94] A. Peters,et al. Association between Severity of Asthma and Degree of Chronic Rhinosinusitis , 2011, American journal of rhinology & allergy.
[95] K. Van Steen,et al. Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma. , 2010, The Journal of allergy and clinical immunology.
[96] J. Sheikh,et al. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab , 2010, Current medical research and opinion.
[97] E. Israel,et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.
[98] James J. Lee,et al. Eosinophils in health and disease: the LIAR hypothesis , 2010, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[99] Parameswaran Nair,et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.
[100] J. Sheikh,et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. , 2009, The Journal of allergy and clinical immunology.
[101] H. Raspe,et al. EULAR recommendations for the management of primary small and medium vessel vasculitis , 2008, Annals of the Rheumatic Diseases.
[102] J. Parkin,et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.
[103] W. Busse,et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.
[104] M. Goldman,et al. Lymphocytic variant hypereosinophilic syndromes. , 2007, Immunology and allergy clinics of North America.
[105] I. Pavord,et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.
[106] R. Pauwels,et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary Updated 2003 , 2004, COPD.
[107] J. Ring,et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. , 2003, The New England journal of medicine.
[108] S. Phipps,et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.
[109] D. Postma,et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.
[110] Peter Marynen,et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.
[111] Lin Ying Liu,et al. Decreased Expression of Membrane IL-5 Receptor α on Human Eosinophils: II. IL-5 Down-Modulates Its Receptor Via a Proteinase-Mediated Process1 , 2002, The Journal of Immunology.
[112] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.
[113] K. Chung,et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.
[114] S. Wenzel,et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.
[115] C. Bachert,et al. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. , 1997, Journal of immunology.
[116] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[117] C. Combadière,et al. Molecular Cloning of Human Eotaxin, an Eosinophil-selective CC Chemokine, and Identification of a Specific Eosinophil Eotaxin Receptor, CC Chemokine Receptor 3 (*) , 1996, The Journal of Biological Chemistry.
[118] P. Foster,et al. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.
[119] J. Bousquet,et al. Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.
[120] G. Gleich,et al. The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.
[121] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[122] F. Moosig,et al. Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome. , 2012, Clinical and experimental rheumatology.
[123] S. Willsie. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .
[124] F. Mellot,et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. , 2010, The Journal of allergy and clinical immunology.
[125] M. Rothenberg,et al. Biology of the eosinophil. , 2009, Advances in immunology.
[126] J. Boyce,et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. , 2004, The Journal of allergy and clinical immunology.
[127] Lin Ying Liu,et al. Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. , 2002, Journal of immunology.